Is there a generic for Acetylcysteine?

Yes. The FDA Orange Book lists 27 approved generic (ANDA) applications for Acetylcysteine, referencing the brand CETYLEV. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Acetylcysteine?

CETYLEV (NDA 207916, ARBOR PHARMS LLC) is the reference-listed drug, the approved product a generic applicant must show its version is the same as.

What patents protect Acetylcysteine?

The Orange Book lists 6 patents against Acetylcysteine products, with the earliest listed expiry in 2026. Listed patents cover the drug substance, drug product, or approved methods of use, and a generic launching before they expire must file a Paragraph IV certification.

Does Acetylcysteine have FDA marketing exclusivity?

Yes. The Orange Book records 1 marketing-exclusivity period for Acetylcysteine. Exclusivity is granted by FDA at approval (for example new-chemical-entity, orphan-drug, or pediatric exclusivity) and runs independently of any listed patents.

What dosage forms of Acetylcysteine are approved?

Acetylcysteine is approved in the following dosage forms: injectable, solution, tablet, effervescent.

FDA Orange Book · active-ingredient family

Acetylcysteine

Acetylcysteine: 3 brands, 27 generics; first approved Oct 14, 1986; generic available.

Generic available1 exclusivity periodHas discontinued products

Generic status & protection

Generic available: 27 ANDA applications approved.

Earliest patent expiry May 21, 2026Latest exclusivity ends Nov 26, 2027

Brands (NDA)

Generics (ANDA)

Listed patents

Next patent expiry

May 21, 2026

3 mo ago

Brand (NDA) products

Originator applications

CETYLEVRLD
ARBOR PHARMS LLCNDA 20791620162 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
500MG TABLET, EFFERVESCENT ORAL Discontinued —
2.5GM TABLET, EFFERVESCENT ORAL Discontinued —
ACETADOTERLDRS
CUMBERLAND PHARMSNDA 0215392004
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
MUCOMYSTRLD
APOTHECONNDA 013601—2 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Discontinued —
10% SOLUTION INHALATION, ORAL Discontinued —

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
500MG	TABLET, EFFERVESCENT	ORAL	Discontinued	—
2.5GM	TABLET, EFFERVESCENT	ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Discontinued	—
10%	SOLUTION	INHALATION, ORAL	Discontinued	—

Generic (ANDA) products (27)

Abbreviated applications

ACETYLCYSTEINE
CONBA USAANDA 21417720252 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Rx AN
20% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINE
SOMERSET THERAPS LLCANDA 21919420252 strengths
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Rx AN
20% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINE
SOMERSET THERAPS LLCANDA 2183972024
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
EXELA PHARMAANDA 2056432023
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Discontinued —
ACETYLCYSTEINE
ONESOURCE SPECIALTYANDA 2171822023
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
REGCON HOLDINGSANDA 2156202022
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
GLENMARK PHARMSANDA 2136932022
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
EXELA PHARMAANDA 2047972021
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Discontinued —
ACETYLCYSTEINE
ZYDUS PHARMSANDA 2081662018
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
SAGENT PHARMS INCANDA 0916842017
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
EUGIA PHARMAANDA 2073582016
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
RISINGANDA 2031732015
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
ALVOGENANDA 2046742014
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINE
FRESENIUS KABI USAANDA 2006442012
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
6GM/30ML (200MG/ML) INJECTABLE INTRAVENOUS Rx AP
ACETYLCYSTEINE
ALVOGENANDA 2038532012
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINERS
AM REGENTANDA 0724891995
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINERS
AM REGENTANDA 0725471995
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINE
HOSPIRAANDA 0736641994
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINE
HOSPIRAANDA 0740371994
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Rx AN
ACETYLCYSTEINE
ROXANEANDA 0726211992
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Discontinued —
ACETYLCYSTEINE
ROXANEANDA 0726221992
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Discontinued —
ACETYLCYSTEINE
ROXANEANDA 0723231992
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Discontinued —
ACETYLCYSTEINE
ROXANEANDA 0723241992
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Discontinued —
ACETYLCYSTEINE
HOSPIRAANDA 0713641989
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Discontinued —
ACETYLCYSTEINE
HOSPIRAANDA 0713651989
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Discontinued —
MUCOSIL-10
DEYANDA 0705751986
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
10% SOLUTION INHALATION, ORAL Discontinued —
MUCOSIL-20
DEYANDA 0705761986
Approved strengths under this FDA application.
Strength Dosage form Route Status TE
20% SOLUTION INHALATION, ORAL Discontinued —

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Rx	AN
20%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Rx	AN
20%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
6GM/30ML (200MG/ML)	INJECTABLE	INTRAVENOUS	Rx	AP

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Rx	AN

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
10%	SOLUTION	INHALATION, ORAL	Discontinued	—

Approved strengths under this FDA application.
Strength	Dosage form	Route	Status	TE
20%	SOLUTION	INHALATION, ORAL	Discontinued	—

Patent & exclusivity timeline

Protection horizon

Patent expiryExclusivity endToday

Marketing exclusivity

Hatch-Waxman

D-196New indication / change exclusivity (3 years)
Nov 26, 2027
in 1 yr 3 mo

Listed patents

Orange Book patent file

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
Patent	Expires	In	Type
8148356	May 21, 2026	3 mo ago	Product
9327028	Jul 21, 2031	in 5 yr	U-1839
8722738	Apr 06, 2032	in 5 yr 8 mo	U-1373
9561204	May 08, 2032	in 5 yr 9 mo	U-1373
8747894	May 08, 2032	in 5 yr 9 mo	ProductU-1373
9427421	May 08, 2032	in 5 yr 9 mo	Product

Approval history

FDA approval span

First approval

Oct 14, 1986

40 yr 5 mo ago

Most recent approval

Mar 14, 2025

1 yr 6 mo ago

Approvals span 1986–2025 across 30 FDA applications.

Brand (NDA) 310%

Generic (ANDA) 2790%

Acetylcysteine: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo